Inclusion Criteria:

          -  Male or female subjects ≥18 years of age, ≥19 years in Korea, or ≥20 years for
             subjects in Japan and Taiwan

          -  Histologically confirmed diagnosis of CD20 positive iNHL with histological subtype
             limited to:

               1. FL Gr 1, Gr 2, or Gr 3a

               2. MZL (splenic, nodal, or extra-nodal)

          -  Subjects with relapsed or refractory disease who received ≥1 prior lines of therapy

          -  Subjects must have at least one bi-dimensionally measurable lesion >1.5 cm

          -  Adequate hematologic parameters at screening unless abnormal values are due to disease

          -  Adequate renal and hepatic function

          -  Adequate cardiac function based on ECG and LVEF assessments

        Exclusion Criteria:

          -  Histologically confirmed diagnosis of FL Gr 3b or transformed disease

          -  Prior therapy with PI3K inhibitors

          -  Ongoing or history of drug-induced pneumonitis

          -  Known lymphomatous involvement of the central nervous system

          -  Tested positive for or active viral infection with hepatitis B or C virus

          -  Tested positive or active infection with human immunodeficiency virus

          -  Tested positive, or active infection with human T-cell leukemia virus type 1

          -  Any uncontrolled clinically significant illness

          -  History of clinically significant cardiovascular abnormalities such as congestive
             heart failure

          -  History of clinically significant gastrointestinal (GI) conditions

          -  Females who are pregnant